Translating clinical trials from human to veterinary oncology and back
Tóm tắt
In human medicine clinical trials are legally required for drug development and approval. In contrast, clinical trials in small animal cancer patients are less common and legally perceived as animal experiments. Comparative oncology has been recognized as a method to speed up the development of medications by introducing animal patients with naturally developing tumours. In such cases, using animal patients would generate more robust data, as their spontaneous disease resembles the “real life” situation and thus could be more likely to predict the situation in human disease. This would not only provide veterinary oncology access to the latest developments in medicine before they are available for clinical use in animals, but could also lead to generation of clinical data in animal patients that could be translated to humans. Nevertheless, there are several limitations to practical conduct of clinical trials in veterinary medicine. In this review, the possible application of similar standards of Good Clinical Practice as in human clinical drug development will be discussed in detail, with special consideration of legal and ethical aspects in Europe and the US.
Tài liệu tham khảo
Stapff M (2008) Die Entwicklung neuer Arzneimittel. Arzneimittelstudien: eine Einführung in klinische Prüfungen für Ärzte, Studenten, medizinisches Assistenzpersonal und interessierte Laien. 5., überarb. Aufl. ed. München i.e. Germering u.a., Zuckschwerdt, pp 8–18
Biooncology (2015) Cancer Clinical Trials—Phases and Design. http://www.biooncology.com/clinical-trials/clinical-endpoints/introduction/. Accessed 03 April 2015
Stapff M (2008) Rechtliche Abgrenzung: Anwendungsbeobachtung vs. klinische Prüfung, Definitionen. Arzneimittelstudien: eine Einführung in klinische Prüfungen für Ärzte, Studenten, medizinisches Assistenzpersonal und interessierte Laien. 5., überarb. Aufl. ed. München i.e. Germering u.a., Zuckschwerdt. pp 29–33
ICH Topic E6 (R1) Guideline for Good Clinical Practice (2002) European Medicines Agency, CPMP/ICH/135/95
Stapff M (2008) Arzneimittelstudien: eine Einführung in klinische Prüfungen für Ärzte, Studenten, medizinisches Assistenzpersonal und interessierte Laien. 5., überarb. Aufl. ed. München i.e. Germering u.a., Zuckschwerdt
Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (2001)
Bundesgesetz vom 2. März 1983 über die Herstellung und das Inverkehrbringen von Arzneimitteln (Arzneimittelgesetz—AMG) (BGBl. Nr. 185/1983), Fassung vom 14.05.2013 (BGBl. I Nr. 48/2013) (2013)
FDA (2015) Regulations Relating to Good Clinical Practice and Clinical Trials. http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm155713.htm—FDA Regulations. Accessed 16 July 2015
Detailed guidance on the European clinical trials database (EUDRACT Database), ENTR/CT 5.1 (2004)
Detailed guidance on the European database of Suspected Unexpected Serious Adverse Reactions (Eudravigilance—Clinical Trial Module), ENTR/CT4 (2004)
FDA (2015) GCP/Clinical Trial Guidance Documents. http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/ucm219433.htm. Accessed 16 July 2015
Stapff M (2008) Good Clinical Practice (GCP) und ICH-GCP. Arzneimittelstudien: eine Einführung in klinische Prüfungen für Ärzte, Studenten, medizinisches Assistenzpersonal und interessierte Laien. 5., überarb. Aufl. ed. München i.e. Germering u.a., Zuckschwerdt, pp 34–39
FDA (2009) Guidance for Clinical Investigators, Sponsors, and IRBs: Adverse Event Reporting to IRBs—Improving Human Subject Protection. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126572.pdf. Accessed 16 July 2015
Rose DM, Marshall R, Surber MW (2015) Pharmaceutical industry, academia and patient advocacy organizations: what is the recipe for synergic (win-win-win) collaborations? Respirology 20(2):185–191. doi:10.1111/resp.12458
Bond K, Spooner C, Tjosvold L, Lemiere C, Rowe BH (2012) The nature and influence of pharmaceutical industry involvement in asthma trials. Can Respir J J Can Thorac Soc 19(4):267–271
Seufferlein T, Adler G (2010) Clinical research in Germany at the example of oncology. Onkologie 33(Suppl 7):1–5. doi:10.1159/000319732
Lundh A, Krogsboll LT, Gotzsche PC (2012) Sponsors’ participation in conduct and reporting of industry trials: a descriptive study. Trials 13:146. doi:10.1186/1745-6215-13-146
Stapff M (2008) Wenn Ärzte von der Pharmaindustrie Geld erhalten: Vorschriften und Fallstricke. Arzneimittelstudien: eine Einführung in klinische Prüfungen für Ärzte, Studenten, medizinisches Assistenzpersonal und interessierte Laien. 5., überarb. Aufl. ed. München i.e. Germering u.a., Zuckschwerdt, pp 120–122
Vetcancertrials.org. Searchable clinical trials database for cancer in pet animals (2015). http://www.vetcancertrials.org/studies. Accessed 18 July 2015
Clinicaltrials.gov. Search: Category Cancers and Other Neoplasms. 2015. http://www.clinicaltrials.gov/ct2/search/browse?brwse=cond_cat_BC04. Accessed 18 July 2015
Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medical products as amended by Directive 2004/28/EC of the European Parliament and the Council of 31 March 2004 (2004)
FDA—New animal drug applications (21 CFR 514) (2014)
Bundesgesetz über Versuche an lebenden Tieren (Tierversuchsgesetz 2012—TVG 2012) vom 28.12.2012 (BGBl. I Nr. 114/2012) (2012)
Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes, L 276/33 (2010)
Guideline on Good Clinical Practice. CVMP/VICH/595/98-FINAL. Topic GL9 (GCP), Step 7 Consensus Guideline (2000)
FDA—Good laboratory practice for nonclinical laboratory studies (21 CFR 58) (2014)
Animal Welfare Act and Animal Welfare Regulations (2013) United States Department of Agriculture. Animal and Plant Health Inspection Service, Washington DC
Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medical products as amended by Directive 2004/28/EC of the European Parliament and the Council of 31 March 2004, Article 13a(1) (2004)
Hampshire VA (2003) Regulatory issues surrounding the use of companion animals in clinical investigations, trials, and studies. ILAR J Natl Res Counc Inst Lab Anim Resour 44(3):191–196
Khanna C, London C, Vail D, Mazcko C, Hirschfeld S (2009) Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res 15(18):5671–5677. doi:10.1158/1078-0432.CCR-09-0719
VMU Wien. Good Scientific Practice. Mitteilungsblatt der Veterinärmedizinischen Universität Wien. 2014;Studienjahr 2013/2014(10):30
Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A et al (2014) Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Mol Cancer Ther 13(7):1777–1790. doi:10.1158/1535-7163.MCT-13-0288
Binder R (2014) Laboratory Animal Law: An Introduction to Its History and Principles. In: Jensen-Jarolim E (ed) Comparative medicine—anatomy and physiology. Springer, Wien, pp 267–280
Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8(2):147–156. doi:10.1038/nrc2273
Marchetti S, Schellens JH (2007) The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 97(5):577–581. doi:10.1038/sj.bjc.6603925
NCCF. National Canine Cancer Foundation (2015). http://www.wearethecure.org. Accessed 18 May 2015
Tierarzneimittelkontrollgesetz—TAKG (BGBl. I Nr. 28/2002), Fassung vom 11.1.2008 (BGBl. I Nr. 36/2008), §4 (2008)
London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP et al (2009) Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res Off J Am Assoc Cancer Res 15(11):3856–3865. doi:10.1158/1078-0432.CCR-08-1860
Jensen-Jarolim E (2014) Definition of comparative medicine: history and new identity. In: Jensen-Jarolim E (ed) Comparative medicine—anatomy and physiology. Springer, Wien, pp 1–18